ClinicalTrials.gg

Hyperaldosteronism clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 201 studies for Hyperaldosteronism across more than 10 countries. 91 are recruiting or about to start. 160 of them are mainly about Hyperaldosteronism (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16.

Status

Completed
74
Recruiting
68
Status unknown
22
Not yet recruiting
19
Active, not recruiting
9
Enrolling by invitation
4

Phase

Phase 2
18
Phase 4
16
Phase 3
6
Phase 1
3
Early Phase 1
1

Where

China
77
United States
19
United Kingdom
16
France
14
Italy
13
Canada
10

Who develops what

Add Hyperaldosteronism to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 5 programs from 5 companies, 5 with this as their studies’ main aim; 1 with a live phase 3 study; 4 primary completions in the next 12 months. Compare AstraZeneca, CSPC Pharmaceutical Group and Jiangsu HengRui Medicine here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 5 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.HRS-1780 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 main aimNCT07470983 A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism — primary endpoint: Change from baseline in office systolic blood pressure (SBP); · 61 enrolled
  • Apr 2027 est.QLS1410 · Qilu Pharmaceutical Co., Ltd. · Phase 2 main aimNCT07550465 Study of QLS1410 in the Treatment of Primary Aldosteronism. — primary endpoint: Change from baseline in seated Systolic Blood Pressure (SBP) at Week 12 · 60 enrolled
  • 1 Apr 2027 est.SAL0140 · Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 2 main aimNCT07646535 A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism — primary endpoint: The baseline change in mean seated systolic blood pressure (msSBP) · 50 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Hyperaldosteronism studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Mineralocorticoid receptor antagonists (MRAs) 7 open · Calcium channel blockers 5

Coming up

24studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 68 Hyperaldosteronism studies recruiting now, 22 (32%) set no upper age limit and 30 (44%) stop at 75 or younger. 6 (9%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 14 (21%) take healthy volunteers.

Recruiting studies that take each age, of 68
AgeWomenMen
104 (6%)4 (6%)
1860 (88%)60 (88%)
3065 (96%)65 (96%)
4066 (97%)66 (97%)
5066 (97%)66 (97%)
6560 (88%)60 (88%)
7546 (68%)46 (68%)
8529 (43%)29 (43%)

Across all 201 studies, recruiting or not: 41% stop at 75 or younger and 14% at 65; 9% take children; <1% are for women only and <1% for men only; 16% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hyperaldosteronism studies take

Of 63 observational studies under Hyperaldosteronism, half reached primary completion within 75 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Interventional, no phase36 mo21–59 · 35 studies——
Observational75 mo32–96 · 63 studies—75 mo32–96 · 63 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 201. Browse all 201 → or search them.